𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A retrospective study of the role of delta agent infection in children with HBsAg-positive chronic hepatitis

✍ Scribed by Giuseppe Maggiore; Michelle Hadchouel; Fausto Sessa; Maria Vinci; Antonio Craxi; Maria D. Marzani; Constantino De Giacomo; Daniel Alagille


Publisher
John Wiley and Sons
Year
1985
Tongue
English
Weight
360 KB
Volume
5
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

✦ Synopsis


The prevalence of intrahepatic delta antigen and/or anti-delta antibody was retrospectively investigated in 102 children with chronic HBsAg-positive hepatitis who were seen consecutively in three medical institutions between 1974 and 1982. Delta infection markers were found in 13 patients (12.7%) who exhibited high serum titers of anti-delta antibody; intrahepatic delta antigen was detected in ten. Eleven of the 13 children had severe progressive liver disease associated in all but one with absence of hepatitis B virus replication as evaluated by analysis of serum hepatitis B virus DNA. The factors which seem to increase the risk of delta infection in children who are hepatitis B virus carriers are geographic origin, a history of exposure to blood derivatives and age. A further 37 of 102 children had chronic active hepatitis (20 patients) or cirrhosis (17 patients) without evidence of delta infection. These results indicate that delta infection occurs in children with chronic hepatitis. This possibility should be considered in investigation of children with HBsAg-positive chronic liver disease. Although the delta agent is an important cause of progressive liver disease in children who are chronic HBsAg carriers, severe liver injury and especially cirrhosis can occur without evidence of delta infection.

~


πŸ“œ SIMILAR VOLUMES


A dose-finding study of once-daily oral
✍ Ching-Lung Lai; Seng Gee Lim; Nathaniel A. Brown; Xiao-Jian Zhou; Deborah M. Llo πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 305 KB πŸ‘ 1 views

Current therapy for chronic hepatitis B is suboptimal as a result of limited durable response rates, cumulative viral resistance, and/or poor tolerability. Telbivudine has potent antiviral activity against hepatitis B virus (HBV) in vitro and in the woodchuck model and has a promising preclinical sa

Development of a hepatitis delta virus a
✍ Liping Shen; Ying Gu; Le Sun; Yingchao Yang; Feng Wang; Yimin Li; Shengli Bi πŸ“‚ Article πŸ“… 2012 πŸ› John Wiley and Sons 🌐 English βš– 83 KB πŸ‘ 2 views

## Abstract Co‐infection with hepatitis delta virus (HDV) and hepatitis B virus (HBV) has been shown to be associated with a more severe form of acute and chronic hepatitis. Cloning and expression of recombinant HDV antigen (rHDAg) in __Escherichiacoli__ are described. Using purified rHDAg, a cost‐

Treatment of children with chronic hepat
✍ Maureen M. Jonas; Joan M. Block; Barbara A. Haber; Saul J. Karpen; W. Thomas Lon πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 437 KB πŸ‘ 2 views

Chronic hepatitis B virus (HBV) infection in children presents a therapeutic challenge for the practitioner. Decisions regarding selection of patients who may benefit from treatment, appropriate timing of treatment, and the choice of antiviral therapy are complex and are compounded by the limited nu

Interferon Ξ±-2b with and without ribavir
✍ Chun-Jen Liu; Ming-Yang Lai; You-Chen Chao; Li-Ying Liao; Sien-Sing Yang; Tun-Je πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 126 KB πŸ‘ 1 views

To study whether interferon (IFN) ␣ and ribavirin combination therapy has a beneficial effect for hepatitis B e antigen (HBeAg)-positive chronic hepatitis B, we enrolled 119 such patients in a randomized study. Fifty-nine patients received 5 million units of IFN-␣2b daily for 4 weeks followed by 5 m